Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALIVUS.NS
Strong BuyPremium GrowerAlivus Life Sciences Limited · Healthcare · India · $1.8B · Avg Vol: $3M/d
91
StockRankGet insider-trade alerts
Q
81
V
31
M
79
P/E (TTM)
28.6x
ROE
16.9%
D/E
0.0x
Dividend %
0.4%
COMPANY DESCRIPTION
Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.5B | 21.8B | 23.4B | 25.0B | 6.9% | 25.9B | 27.9B | 31.4B | 11.9% |
| EPS (INR) | 38.11 | 38.43 | 39.63 | 45.99 | 6.5% | 48.98 | 53.25 | 60.73 | 14.9% |
| Shares | 122.5M | 122.5M | 122.5M | 122.7M | +0.2% | 122.8M | — | — | — |
| Debt | 193.6M | 171.5M | 566.1M | 567.7M | 43.1% | 567.7M | — | — | — |
| Equity | 21.4B | 23.3B | 28.2B | 33.3B | 15.9% | — | — | — | — |
| Op CF | 3.1B | 4.1B | 3.9B | 5.7B | 22.7% | 5.7B | — | — | — |
| Inv CF | -1.5B | -1.2B | -6.2B | -5.7B | — | — | — | — | — |
| Fin CF | -3.9B | -2.8B | -62.3M | -643.4M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+25.5%
SMA 50SMA 200
Close
$14.72
RSI (14)
56.3
52W High
$15.65
From 52W High
0.9%
SCORE BREAKDOWN
Quality
81
ROIC
21.8%91.8
ROE
16.9%85.1
GP/Assets
38.6%76.1
Op. Margin
29.8%91.9
FCF/Assets
6.5%76.0
Piotroski
668.8
Int. Cover
50.0x89.2
D/E Ratio
0.02x81.1
Current Ratio
5.21x73.3
Value
31
P/E (TTM)
28.6x41.5
EV/EBITDA
19.2x36.6
P/FCF
65.4x23.1
P/B
5.2x27.5
P/S
6.6x34.8
Div Yield
0.4%10.4
Momentum
79
52W High %
94%92.0
RS 6M
54%91.7
SMA 50/200
1.21x88.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+28%41.0
Q Growth
32%64.9
FUNDAMENTALS
Market Cap
$1.8B
P/E (Forward)
22.3x
Gross Margin
59.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALIVUS.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALIVUS.NS | Alivus Life Sciences Limited(you) | $1.8B | 91 | Strong Buy |
| APLLTD.NS | Alembic Pharmaceuticals Limited | $1.7B | 84 | Strong Buy |
| CAPLIPOINT.NS | Caplin Point Laboratories Limited | $2.2B | 86 | Strong Buy |
| GRANULES.NS | Granules India Limited | $2.3B | 87 | Strong Buy |
| VIYASH.NS | Viyash Scientific Limited | $1.2B | 88 | Strong Buy |
| STAR.NS | Strides Pharma Science Limited | $1.2B | 93 | Strong Buy |
| AKUMS.NS | Akums Drugs and Pharmaceuticals Limited | $1.2B | 95 | Strong Buy |
| PGHL.NS | Procter & Gamble Health Limited | $981M | 92 | Strong Buy |
| BLISSGVS.NS | Bliss GVS Pharma Limited | $810M | 87 | Strong Buy |
| SPARC.NS | Sun Pharma Advanced Research Company Limited | $696M | 89 | Strong Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%